NewsRoom Articles - Page 96 of 154 - PsychedelicNewsWire (PNW)

WednesdayJun 02, 2021 1:30 pm

Peyote: The Less-Known Psychedelic with Numerous Benefits

Psychedelics such as LSD, MDMA, ayahuasca and psilocybin have become popular in the last few years as researchers discover more about the substances and the therapeutic benefits they possess. While these substances have been a part of the popular culture in the West for some decades now, other psychedelics, including peyote, have been used by Indigenous people in spiritual and healing practices for many millennia. Peyote, which is a less-popular psychedelic, is a spineless cactus that naturally grows in various parts of Mexico and Southern Texas. The cactus is small and bears the shape of a caterpillar cocoon, which explains…

WednesdayJun 02, 2021 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial The company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, Germany Pilot project involving rapid COVID-19 PCR tests has been initiated in Germany, promising efficacy and accuracy of results in as little as 25 minutes XPhyto is currently in talks and negotiations with distribution and wholesale partners, with a potential…

TuesdayJun 01, 2021 1:00 pm

California Bill to Legalize Psychedelic Possession to Be Advanced to Senate Floor

A measure to legalize the possession of psychedelic substances in the state of California may soon advance to the Senate. The bill, which was sponsored by Sen. Scott Wiener, has already been approved by two policy committees. However, it will need to be approved by the Senate Appropriations Committee so that it can be added to the Senate calendar. It was cleared by the panel in a 5-to-2 vote. The full chamber may begin debates on the reform initiative by June 4. If it is approved, the initiative will be advanced to the Assembly, and then possibly to the governor’s…

FridayMay 28, 2021 12:00 pm

Drug Developer Opts for RWE Model to Study Psychedelic Therapies

Albert Labs, a UK-based R&D company, is exploring a new way to fast track how quickly patients can access psychedelic therapies by leveraging Real World Evidence (“RWE”) while developing the medicines needed to manage a variety of mental health ailments. While the current range of pharmaceutical medicines for mental health issues is diverse, an increasing number of patients aren’t responding to these conventional treatments. Additionally, some mental health issues seem to have no current treatment modality indicated for them. A case in point is cancer-induced anxiety, which can lower treatment compliance rates and even drive up the number of suicides…

FridayMay 28, 2021 11:31 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development Bio-pharmaceutical…

ThursdayMay 27, 2021 12:30 pm

Legendary Investor Believes Investment Potential of Psychedelics Exceeds That of Marijuana

Psychedelics drugs are becoming more popular as more research discovers the potential they possess for treating various mental health conditions. These substances have been ignored since the 1960s, and while they are still illegal in various states across the country, many companies are betting that the substances will be big, given both the anecdotal and preliminary scientific evidence showing that the compounds may be even more efficacious than the current pharmaceuticals prescribed to manage various disorders. These findings have garnered the attention of many, from Wall Street to independent investors, who believe that psychedelics will be huge in the near…

WednesdayMay 26, 2021 2:30 pm

Psychedelic Expert Thinks Legalizing Psychedelic Medicine May Put End to Persecution, Incarceration of Minorities

For many centuries now, psychedelics have been used by various communities and groups. Many doubt that there’s a human society in recorded history that hasn’t used psychedelics to experiment with altered states of consciousness. It is well known that psychedelics have been used by various indigenous groups of the Americas and are regarded as sacred plants. The plants have been used to explain the myths regarding the existence of humans on earth, teach younger generations, develop socializations and guide cultures. However, the use of psychedelics isn’t exclusive to indigenous groups, as records show that ancient Greeks also used the natural…

WednesdayMay 26, 2021 9:00 am

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules. “By continuing to innovate in directions to enhance the patient experience and…

TuesdayMay 25, 2021 2:15 pm

Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs

Daniel Carcillo retired from the National Hockey League in 2015, after nine seasons in the game. He had been diagnosed with several concussions and had struggled with insomnia, depression, anxiety, headaches and even slurred speech in his professional seasons as a hockey player. Determined to get better, Carcillo implemented lifestyle changes that included the use of psilocybin, an active ingredient found in magic mushrooms, as well as eating healthier and getting more sleep. This, he said, helped improve his overall heath tremendously. He is now dedicating his life to helping other individuals like himself as well as athletes who have…

MondayMay 24, 2021 3:00 pm

FDA Grants Authorization Allowing Research Institute to Study Psychedelic Use by Therapists

The Multidisciplinary Association for Psychedelic Studies (“MAPS”) was recently granted authorization to administer MDMA to therapists. This comes after the FDA, which gave its approval, also allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD. The therapists, who have all volunteered, are currently undergoing training on how to treat individuals suffering from post-traumatic stress disorder and will be allowed to take part in phase 1 trials in an attempt to acquire personal experience from this treatment option. This complementary research project will be conducted by MAPS, which is also conducting phase 3 clinical trials…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000